HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
北海道大学病院  >
雑誌発表論文等  >

A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero-Incretin Study 1 (SAIS1)

この資料はクリエイティブ・コモンズ・ライセンスの下で公開されています。

フルテキスト
journal.pone.0164255.s006.TIFS3 Table121.1 kBTIFF見る/開く
journal.pone.0164255.s005.XLSXS2 Table35.37 kBMicrosoft Excel見る/開く
journal.pone.0164255.s004.XLSXS1 Table40.17 kBMicrosoft Excel見る/開く
journal.pone.0164255.s003.DOCS2 Protocol134.5 kBMicrosoft Word見る/開く
journal.pone.0164255.s002.DOCXS1 Protocol58.3 kBMicrosoft Word見る/開く
journal.pone.0164255.s001.DOCXS1 Consort Checklist50.16 kBMicrosoft Word見る/開く
journal.pone.0164255.pdf862.48 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/63828

タイトル: A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters : Sapporo Athero-Incretin Study 1 (SAIS1)
著者: Nomoto, Hiroshi 著作を一覧する
Miyoshi, Hideaki 著作を一覧する
Furumoto, Tomoo 著作を一覧する
Oba, Koji 著作を一覧する
Tsutsui, Hiroyuki 著作を一覧する
Inoue, Atsushi 著作を一覧する
Atsumi, Tatsuya 著作を一覧する
Manda, Naoki 著作を一覧する
Kurihara, Yoshio 著作を一覧する
Aoki, Shin 著作を一覧する
発行日: 2016年10月 6日
出版者: The Public Library of Science
誌名: PLoS ONE
巻: 11
号: 10
開始ページ: e0164255
出版社 DOI: 10.1371/journal.pone.0164255
抄録: Objectives; The DPP-4 inhibitors are incretin-related drugs that improve hyperglycemia in a glucose-dependent manner and have been reported to exert favorable effects on atherosclerosis. However, it has not been fully elucidated whether DPP-4 inhibitors are able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of sitagliptin, a DPP-4 inhibitor, on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride. Materials and Methods: In this multicenter, prospective, randomized parallel-group comparison study, 103 outpatients with type 2 diabetes (aged 59.9 +/- 9.9 years with HbA1c levels of 7.5 +/- 0.4%) with dietary cure only and/or current metformin treatment were enrolled and randomly assigned to receive sitagliptin or glimepiride therapy once daily for 26 weeks. Flow-mediated dilation (FMD), a comprehensive panel of hemodynamic parameters (Task Force(R) Monitor), and serum metabolic markers were assessed before and after the treatment. Results: During the study period, no statistically significant change in %FMD was seen in both groups (sitagliptin, 5.6 to 5.6%; glimepiride, 5.6 to 6.0%). Secretory units of islets in transplantation, TNF-α, adiponectin and biological antioxidant potential significantly improved in the sitagliptin group, and superoxide dismutase also tended to improve in the sitagliptin group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different. Conclusions: Regardless of glycemic improvement, early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta-cell function and on inflammatory and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis.
資料タイプ: article
URI: http://hdl.handle.net/2115/63828
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 三好 秀明

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学